American Well Corp Stock Price, News & Analysis

Amwell (NYSE: AMWL) has announced a significant inducement grant to its new chief product and technology officer, Dan Zamansky. The grant consists of restricted stock units (RSUs) covering 220,844 shares of Class A common stock.

The vesting schedule includes:

• 25% vesting after six months (Initial Vesting Date)
• Remaining 75% vesting in equal increments every three months
• Full vesting occurs four years from grant date

If terminated without cause or with good reason, Zamansky's RSUs will continue vesting through the first anniversary of termination. In case of involuntary termination one month before or within 24 months after a change in control, all RSUs will immediately vest. The grant was approved under Amwell's Inducement Plan and NYSE Rule 303A.08.

Amwell (NYSE: AMWL) has appointed Dan Zamansky as its new chief product and technology officer, effective March 03, 2025. Zamansky, an Amazon veteran with over a decade of experience, will lead the company's product and R&D organizations.

At Amazon, Zamansky founded and led AWS Health AI, the company's cloud initiative focused on democratizing AI technology access for healthcare customers. He also managed product and technology teams across AWS and Amazon Ads initiatives.

In his new role, Zamansky will focus on Amwell's technology-enabled care platform for payers and health systems, ensuring its evolution to meet increasing online care demands. He succeeds Vaughn Paunovich, who has served since 2022 and led the company through a re-platforming phase.

Amwell (NYSE: AMWL) has announced the issuance of Restricted Stock Units (RSUs) to four new employees as employment inducements. The grants, approved by the company's Compensation Committee, total 16,737 shares of Class A common stock. The vesting schedule includes 25% of RSUs vesting on the first anniversary of the grant date, with the remaining 75% vesting in equal increments every three months over the following three years, contingent on continued employment. These grants were made under Amwell's Inducement Plan and comply with NYSE's Listed Company Manual Rule 303A.08.

Amwell (NYSE: AMWL), a leading SaaS-based healthcare platform provider, has announced its participation in the TD Cowen 24th Annual Health Care conference in Boston. Dr. Ido Schoenberg, Amwell's chairman and CEO, will engage in a fireside chat on March 4 at 9:10 a.m. ET, along with one-on-one meetings during the conference. Investors can access the audio webcast of the fireside chat through the company's investor relations website at investors.amwell.com.

Amwell (NYSE: AMWL), a provider of SaaS-based technology-enabled healthcare platform, has announced its financial results for the fourth quarter and full year 2024. The company will discuss these results during a conference call scheduled for February 12, 2025, at 5 p.m. ET. Investors can access the earnings report through Amwell's investor relations website, and a live audio webcast of the conference call will be available. A replay of the call will be accessible via webcast on the investor relations website after the event.

Amwell (NYSE: AMWL) has announced it will release its fourth quarter and full year 2024 operating results after market close on Wednesday, February 12, 2025. The company will host a conference call and webcast at 5:00 PM ET on the same day, where management will discuss the financial results and provide business updates. The earnings report and webcast will be accessible through the Investors section of Amwell's website, with a replay available for approximately 90 days at investors.amwell.com.

Amwell (NYSE: AMWL) has announced the addition of Vida Health to its clinical programs portfolio, expanding its virtual cardiometabolic care offerings. The new program, Amwell Cardiometabolic Care Powered by Vida, will provide obesity and diabetes care services, including GLP-1s and anti-obesity medications, through Amwell's platform to health plans and employers.

The program will offer personalized care considering social factors like food security, financial barriers, and cultural norms. Vida's services will integrate with Amwell's existing virtual primary care, urgent care, and behavioral health programs. The partnership aims to address the significant healthcare challenge of obesity, which affects over 40% of American adults and, combined with diabetes, costs the U.S. healthcare system more than $500 billion annually.

The collaboration focuses on delivering value-based, outcomes-driven care through lifestyle interventions and Medical Nutrition Therapy, providing members with a unified entry point for clinical and behavioral health support.

Amwell (NYSE: AMWL) has announced the sale of its Amwell Psychiatric Care (APC) business to Avel eCare for approximately $21M in cash, plus an additional earn-out payment. The divestment includes APC technology, personnel, and the Asana psychiatric clinical network.

The strategic move aims to sharpen Amwell's focus on key growth areas and its unified digital care platform. Through Amwell Medical Group (AMG), the company will continue providing behavioral health services, including AMG Therapy Services and SilverCloud digital behavioral health.

Amwell has reiterated its 2024 guidance, projecting:

• Revenue between $247-252 million
• Adjusted EBITDA between ($137)-($142) million
• AMG visits between 1.4-1.5 million

The company maintains its goal of achieving positive cash flow in 2026.

Amwell (NYSE: AMWL) has announced that CFO Mark Hirschhorn will expand his role to include Chief Operating Officer responsibilities, effective January 1, 2025. While maintaining his CFO duties, Hirschhorn will oversee operational and growth strategies, including clinical, sales, and marketing teams. The company aims to streamline its portfolio and pursue profitable growth, targeting cash flow positivity by 2026.

As part of the organizational restructuring, two executives will depart at year-end: Chief Commercial and Growth Officer Kathy Weiler and current COO Kurt Knight. Weiler contributed to cost initiatives and growth organization transformation, while Knight's 14-year tenure included key roles in strategy, M&A, IPO, COVID-19 operations scaling, and managing Amwell Medical Group.